March 2nd 2011 | Biologics, Health care system, Public policy issues, psoriatic arthritis | 1 Comment
We’re happy to see the Phil Mickelson psoriasis, psoriatic arthritis, and RA campaign launch. Go Phil! We hope he is winning again soon.
The campaign is called On Course with Phil, and you can see the site here: http://www.oncoursewithphil.com .
The campaign is owned by Amgen & Pfizer (they market the popular biologic Enbrel [etanercept]). Our only
READ THE FULL POST
February 10th 2011 | Alternative/buyer beware/natural, Health care system, Public policy issues, Treatment | 7 Comments
Are you paying too much for nonprescription psoriasis treatments? Many psoriasis patients are paying WAY too much for 2% coal tar and other common psoriasis treatments.
Post a comment below or email us [ info@psoriasis-cure-now.org ] with your most expensive NON-prescription meds; we’re going to start calling out these overpriced products and their doctor and nonprofit
READ THE FULL POST
October 6th 2010 | Biologics, Health care system, Public policy issues, psoriatic arthritis | 0 Comments
In what may be a look at the future of the U.S. health care system, the National Institute for Health and Clinical Excellence (NICE) in Britain has recommended denying psoriatic arthritis patients reimbursement for the biologic Simponi (golimumab) in the country’s government-run health care system.
NICE has generated great controversy in the United States, with President
READ THE FULL POST
October 5th 2010 | Biologics, Health care system, Insurance, Public policy issues | 0 Comments
New York Governor David Patterson recently signed many new measures into law, including one that could benefit psoriasis and psoriatic arthritis patients being treated with biologics:
Among the bills signed by Governor Paterson is S.5000-B/A.8278-B, which will codify in law the currently regulatory authority of the State Insurance Department to disapprove requests from insurance carriers
READ THE FULL POST
September 30th 2008 | Alternative/buyer beware/natural, Health care system, Treatment | 0 Comments
From the New York Times:
Can online information be trusted? The answer, increasingly, is yes. In a study earlier this year, a report in the journal Cancer looked at 343 Web pages about breast cancer that came up in online searches. The researchers found 41 inaccurate statements on 18 sites — an error rate of 5.2
READ THE FULL POST
September 1st 2008 | Biologics, Health care system, Psoriasis Research, Public policy issues | 0 Comments
Congress is considering several bills that would make it easier for companies to market generic versions of biologic drugs, according to a recent article in the Washington Post. Competition from generics is expected to reduce significantly the cost of expensive biologic medications. The Congressional Budget Office estimates that the availability of biologic generics would
READ THE FULL POST
August 16th 2008 | Health care system, Insurance, Treatment | 3 Comments
A European study has confirmed what psoriasis patients whisper about among themselves: a stunning percentage of psoriasis patients do not even fill the prescriptions their doctors prescribe for them. Nearly one-third of dermatology patients do not obtain their prescription medications, found the study from Denmark, and psoriasis patients had the lowest compliance rate–nearly
READ THE FULL POST
August 7th 2008 | Health care system, Impact of psoriasis, Insurance, Public policy issues, Treatment | 0 Comments
The Washington Post reported on August 4 that health and life insurance companies can cheaply and quickly get access to electronic prescription records of insurance applicants. At a cost of about $15 per request, private companies, including Milliman IntelliScript and Ingenix, will compile an insurance applicant’s prescription history from databases of past insurance claims. Both
READ THE FULL POST
March 19th 2008 | Health care system | 0 Comments
An article in the New York Times (free registration may be required) makes several note-worthy points. The article talks about how extremely difficult it is for medical students to be selected to study dermatology–difficult because so many very smart people want the same few training spots available. It turns out relatively humane hours,
READ THE FULL POST
February 22nd 2008 | Health care system, Public policy issues | 0 Comments
A study of psoriasis treatment in hospital dermatology departments in the United Kingdom has found that “the average waiting time for routine appointments is only 10 weeks….”
It’s unclear how “routine” is defined, but ten weeks would be a terribly long time if you were in the midst of a psoriasis flare.
How does that wait compare
READ THE FULL POST
